11 / 22
conferenceseries LLC Ltd
Notes:
Page 42
Clinical Pharmacology & Biopharmaceutics | ISSN : 2167-065X
Volume 7
September 18-19, 2018 | Amsterdam, Netherlands
6
th
European Biopharma Congress
Euro Biopharma 2018
Fast dissolving drug delivery systems
Gülay Yelken Demirel
University of Gazi , Turkey
F
ast-dissolving formulations represent excellent opportunities for life cycle management to the pharmaceutical companies. Fast dissolving
technologies have many advantages like ease of swallowing, administration without water, quick onset of action for improving both
patient convenience and compliance as benefits for the patient; extended life cycle, product differentiation, patent protection as benefits
for pharmaceutical companies. But there are some challenges for formulation development studies like taste -masking, disintegration
time, moisture sensitivity, friability, packaging and intellectual property issues, especially for the generic companies. The technologies are
under patent protection like Zydis
®
, Flashtab
®
, OraSolv
®
and DuraSolv™, and WOWTAB
®
. One of the major issues is a taste-masking
problem may be overcome with using cyclodextrins, polymer coating, flavoring and sweetening agent, microencapsulation techniques.
There are some modified excipients for providing both taste-masking and product ability properties in the formulation like Ludiflash®
and Pharmaburst
®
. From the analytical development point of view, there are several different methods from conventional dosage forms
which are determined in the Pharmacopoeias. And for comparison and assessment of taste masking, electronic tongue may be a good
opportunity, which was developed by Alpha MOS. In the sense of generic companies, developing a fast dissolving tablets version of an
existing immediate-release product means that the two formulations must be bioequivalent, and this can be challenging for in-vivo studies,
especially if the method of taste masking retards the dissolution rate of the active ingredient after disintegration. What about the future of
fast dissolving technologies? Orally disintegrating extended Release (ODT-ER) dosage forms are providing all of the benefits of these two
drug delivery technologies in a single pharmaceutical product. And oral rapid films also may be a good alternative, especially for the OTC
market.
gulayelken@gmail.comClin Pharmacol Biopharm 2018, Volume:7
DOI: 10.4172/2167-065X-C1-029